Lung Cancer Medicare Access to Precise Testing Act
Term Dictionary
If you come across any unfamiliar words while reading, these resources can help make everything clearer. Pick whichever one works best for you!
- Congress.gov Legislative Glossary - Comprehensive congressional terms
- NVFC Congressional Terms Glossary - Concise, easy-to-understand definitions
The gist
- Forces Medicare to cover 100% of lung cancer biomarker testing for diagnosed patients starting January 1, 2027, with no patient cost-sharing.
Who wins, who loses
- Wins: Medicare patients with lung cancer, oncologists, genetic testing labs, makers of targeted cancer drugs.
- Loses: Medicare trust fund pays more; taxpayers cover added costs.
What it does
- Amends Title XVIII of the Social Security Act to add biomarker testing as a covered Medicare benefit.
- Defines testing as analysis of tissue, blood, or bodily fluids to find cancer-linked genes, proteins, or molecules.
- Sets Medicare payment at 100% of reasonable charges ā€” no copay or deductible.
- Coverage kicks in for tests furnished on or after January 1, 2027.
Why should I care?
Lung cancer kills more Americans than any other cancer. Supporters say biomarker testing matches patients to targeted drugs that work better than blind chemo, saving lives. Critics argue Medicare already covers medically necessary tests and worry about expanding 100% coverage when the program faces funding shortfalls. Where do you land? Vote below and use "Tell Your Rep" to make sure your voice reaches Congress.